drugset

drugset / Trial / NCT05572333

Clinical Trial to Investigate the Safety and Tolerability of EP395 in Patients With COPD

NCT05572333 ↗

Phase 2 Completed 61 enrolled EpiEndo Pharmaceuticals FGK Clinical Research GmbH · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this clinical trial is to investigate the safety and tolerability of oral, once-daily EP395 administration in COPD patients for 12 weeks.

Timeline

Start: 2022-11-22
Primary completion: 2023-11-24
Completion: 2023-11-24

Publications

Results Watz H, Korn S, Kornmann O, Singh D, Wilkinson T, Hanrott K, Staples KJ, Ackland J, Norris V. A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients. ERJ Open Res. 2026 May 26;12(3):00782-2025. doi: 10.1183/23120541.00782-2025. eCollection 2026 May.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	glasmacinal	Small molecule	—	Oral

Indications